NASDAQ:BDSI - Nasdaq - Common Stock
5.59
0 (-0.09%)
The current stock price of BDSI is 5.59 null. In the past month the price increased by 0.72%. In the past year, price increased by 53.15%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
BIODELIVERY SCIENCES INTL
4131 Parklake Ave Ste 225
Raleigh NORTH CAROLINA 27612 US
CEO: Jeffrey Bailey
Employees: 200
Company Website: https://www.bdsi.com/
Phone: 19195829050.0
The current stock price of BDSI is 5.59 null. The price decreased by -0.09% in the last trading session.
The exchange symbol of BIODELIVERY SCIENCES INTL is BDSI and it is listed on the Nasdaq exchange.
BDSI stock is listed on the Nasdaq exchange.
13 analysts have analysed BDSI and the average price target is 5.48 null. This implies a price decrease of -1.88% is expected in the next year compared to the current price of 5.59. Check the BIODELIVERY SCIENCES INTL stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIODELIVERY SCIENCES INTL (BDSI) has a market capitalization of 552.29M null. This makes BDSI a Small Cap stock.
BIODELIVERY SCIENCES INTL (BDSI) currently has 200 employees.
BIODELIVERY SCIENCES INTL (BDSI) has a support level at 5.58 and a resistance level at 5.6. Check the full technical report for a detailed analysis of BDSI support and resistance levels.
The Revenue of BIODELIVERY SCIENCES INTL (BDSI) is expected to grow by 22.27% in the next year. Check the estimates tab for more information on the BDSI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BDSI does not pay a dividend.
BIODELIVERY SCIENCES INTL (BDSI) will report earnings on 2022-05-04.
The PE ratio for BIODELIVERY SCIENCES INTL (BDSI) is 6.73. This is based on the reported non-GAAP earnings per share of 0.83 and the current share price of 5.59 null. Check the full fundamental report for a full analysis of the valuation metrics for BDSI.
ChartMill assigns a technical rating of 8 / 10 to BDSI. When comparing the yearly performance of all stocks, BDSI is one of the better performing stocks in the market, outperforming 97.69% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to BDSI. While BDSI has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months BDSI reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 232% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 50.91% | ||
ROA | 26.14% | ||
ROE | 45.18% | ||
Debt/Equity | 0.29 |
ChartMill assigns a Buy % Consensus number of 74% to BDSI. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -57.48% and a revenue growth 22.27% for BDSI